Aurora Cannabis Rewrites Its Valuation Amid International Medical Growth

Aurora Cannabis is showcasing a pricing gap that fails to reflect the value uplift generated by its international medical growth.

International Medical Expansion vs. Canadian Pricing Reset

■International medical cannabis revenue rose 17% to C$43.3 million, reinforcing the company's leadership in global medical markets.

■A 30% cut in Canadian federal medical reimbursements drove a 9% decline in total net revenue, largely offset by overseas sales.

■Germany remains the primary driver, accounting for 64% of international revenue, buoyed by high patient demand and two proprietary cultivars ranking among the top five sellers.

Financial Performance Snapshot

■Adjusted EBITDA stood at C$3.4 million, down 68% YoY; margin slipped to 5.1%.

■Adjusted gross margin hit 58%, sitting at the high end of FY27 guidance.

■Net revenue was C$67.6 million, down 9% YoY, with the medical segment comprising 95% of consolidated revenue.

■Free cash flow recorded a C$5.8 million outflow, contrasting with a C$6.8 million inflow a year earlier.

Valuation & Liquidity Edge

■FY27E P/S ratio of 0.92x and FY27E EV/EBITDA of 4.95x position the stock as an attractive acquisition target.

■C$149.1 million in cash and short‑term investments, combined with a debt‑free balance sheet, provide strategic flexibility.

■C$46.4 million of restricted cash will become unrestricted by Q3 FY27, lifting deployable liquidity to C$146.4 million.

Strategic Expansion & GMP Certification

■Safari and Leuna projects, backed by EU‑GMP certification, enable internal supply for high‑margin international markets.

■Proprietary genetics can boost yields by up to 40% on the same cost base, driving production efficiency and pricing power.

Markets are likely to price Aurora Cannabis higher than current valuations reflect, given the robust international medical growth and debt‑free liquidity position. Nonetheless, the sustainability of the Canadian reimbursement cut and the impact of U.S. regulatory developments remain key risk considerations.